ðɪ ɐbˈɪləɾi tʊ ɐtˈɛnjuːˌeɪt ˌɪnfluːˈɛnzə vˈaɪɹəsᵻz baɪ tɹʌŋkˈeɪʃən ʌvðɪ ˌɛnˈɛs wˈʌn pɹˈoʊtiːn pɹˈɛzənts ɐ nˈɑːvəl ɐpɹˈoʊtʃ ɪn dɪzˈaɪn ænd dɪvˈɛləpmənt ʌvðə nˈɛkst dʒˌɛnɚɹˈeɪʃən lˈaɪvɐtˈɛnjuːˌeɪɾᵻd ˌɪnfluːˈɛnzə væksˈiːnz fɔːɹ bˈoʊθ pˈoʊltɹi ænd hjˈuːmənz.
The ability to attenuate influenza viruses by truncation of the NS1 protein presents a novel approach in design and development of the next generation live-attenuated influenza vaccines for both poultry and humans.